Chief Financial Officer
Ian Sanderson joined Boston Pharmaceuticals in 2016 from Catabasis Pharmaceuticals, where he was Chief Financial Officer and oversaw operations. He led the re-positioning and successful IPO of Catabasis in 2015. Prior to joining Catabasis, Ian was a senior advisor with JSB Partners, advising life sciences companies on corporate finance, M&A and business development transactions. Before JSB Partners, Ian spent 20 years with Cowen and Company, most recently as a Managing Director and Senior Pharmaceuticals Analyst, leading Cowen's emerging and specialty pharmaceuticals research team. During his career at Cowen, Ian was named to several Institutional Investor Analyst All Star teams for his coverage of the specialty pharmaceuticals sector, and helped build one of the top-ranked healthcare research teams on Wall Street.
Prior to his pharmaceuticals research analyst career, Ian was a health care investment banker with Cowen and Houlihan Lokey. He began his healthcare career in the finance group of U.S. Surgical Corporation (now Medtronic).
Ian earned a BA in political economy from Williams College and an MBA in finance from the Wharton School.